Vertex Pharmaceuticals Inc (VRTX)

[surf1944]

Vertex Pharmaceuticals cut to neutral at Susquehanna
By Simon Kennedy
Last update: 8:20 a.m. EDT Aug. 6, 2008
LONDON (MarketWatch) -- Susquehanna Financial downgraded Vertex Pharmaceuticals Inc. (VRTX:
Vertex Pharmaceuticals Inc

VRTX 31.16, -0.05, -0.2%) to neutral from positive, citing the Phase II trial results for Schering-Plough's boceprevir hepatitis C drug, which is a likely competitor to Vertex Pharma's telaprevir. The results could indicate that the efficacy advantage previously believed to be held by telaprevir will be diminished, Susquehanna said.